Yes, recent article published today with this stat
Post# of 154127
(Total Views: 482)
Posted On: 10/23/2020 3:33:59 PM
Yes, recent article published today with this statement confirms we are seeking m/m approval in the Philippines:
"By bringing this innovative drug to the Philippines, Chiral Pharma aims to help decrease the number of COVID-19 patients progressing to more severe cases in the country."
However, I disagree with some comments, stating we can't apply for s/c overseas, because we can't give them Phase III s/c Interim data. We can give them IMO, enough data to justify choosing Leronlimab over Remdesivir, You know the data, some of which I'll list:
1) good news/recommendations from DSMC to continue with no issues, no changes, safety & efficacy support continuing, in fact, to only 293 for 2nd look
2) eIND trial results
3) Phase II m/m mild results: Stat Sig on Secondary Endpoint NEWS2 & Clinical Sig on difficult to achieve Primary Endpoint
4) Dr Patterson on Ted Talks, LL is the cure
5) Dr Yo and Dr Been, #1 in Leronlimab, MOA is the best science
6) UCLA and hospitals and doctors reporting amazing results
7-15) etc. etc.
"By bringing this innovative drug to the Philippines, Chiral Pharma aims to help decrease the number of COVID-19 patients progressing to more severe cases in the country."
However, I disagree with some comments, stating we can't apply for s/c overseas, because we can't give them Phase III s/c Interim data. We can give them IMO, enough data to justify choosing Leronlimab over Remdesivir, You know the data, some of which I'll list:
1) good news/recommendations from DSMC to continue with no issues, no changes, safety & efficacy support continuing, in fact, to only 293 for 2nd look
2) eIND trial results
3) Phase II m/m mild results: Stat Sig on Secondary Endpoint NEWS2 & Clinical Sig on difficult to achieve Primary Endpoint
4) Dr Patterson on Ted Talks, LL is the cure
5) Dr Yo and Dr Been, #1 in Leronlimab, MOA is the best science
6) UCLA and hospitals and doctors reporting amazing results
7-15) etc. etc.
(2)
(2)